• Online Features  This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (22)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Neurology  • Movement Disorders  • Parkinson Disease/ Parkinsonian Disorders  • Alert me on articles by topic  Social Bookmarking   What's this?

Lisa M. Shulman, MD; Ann L. Gruber-Baldini, PhD; Karen E. Anderson, MD; Paul S. Fishman, MD, PhD; Stephen G. Reich, MD; William J. Weiner, MD

Arch Neurol. 2010;67(1):64-70.

Objective  To determine the estimates of minimal, moderate, and large clinically important differences (CIDs) for the Unified Parkinson's Disease Rating Scale (UPDRS).

Design  Cross-sectional analysis of the CIDs for UPDRS total and motor scores was performed on patients with Parkinson disease (PD) using distribution- and anchor-based approaches based on the following 3 external standards: disability (10% on the Schwab and England Activities of Daily Living Scale), disease stage (1 stage on the Hoehn and Yahr Scale), and quality of life (1 SD on the 12-Item Short Form Health Survey).

Setting  University of Maryland Parkinson Disease and Movement Disorders Center,

Patients  Six hundred fifty-three patients with PD.

Results  A minimal CID was 2.3 to 2.7 points on the UPDRS motor score and 4.1 to 4.5 on the UPDRS total score. A moderate CID was 4.5 to 6.7 points on the UPDRS motor score and 8.5 to 10.3 on the UPDRS total score. A large CID was 10.7 to 10.8 points on the UPDRS motor score and 16.4 to 17.8 on the UPDRS total score.

Conclusions  Concordance among multiple approaches of analysis based on subjective and objective data show that reasonable estimates for the CID on the UPDRS motor score are 2.5 points for minimal, 5.2 for moderate, and 10.8 for large CIDs. Estimates for the UPDRS total score are 4.3 points for minimal, 9.1 for moderate, and 17.1 for large CIDs. These estimates will assist in determining clinically meaningful changes in PD progression and response to therapeutic interventions.

Author Affiliations: Departments of Neurology (Drs Shulman, Anderson, Fishman, Reich, and Weiner), Epidemiology and Preventive Medicine (Dr Gruber-Baldini), and Psychiatry (Dr Anderson), University of Maryland School of Medicine, Baltimore.

CiteULike    Connotea    Delicious    Digg    Facebook    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLE

This Month in Archives of Neurology
Arch Neurol. 2010;67(1):13-14.
FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Effectiveness of Intensive Inpatient Rehabilitation Treatment on Disease Progression in Parkinsonian Patients: A Randomized Controlled Trial With 1-Year Follow-up
Frazzitta et al.
Neurorehabil Neural Repair 2012;26:144-150.
ABSTRACT | FULL TEXT  

Extended-release pramipexole in early Parkinson disease: A 33-week randomized controlled trial
Poewe et al.
Neurology 2011;77:759-766.
ABSTRACT | FULL TEXT  

Virtual Reality for Gait Training: Can It Induce Motor Learning to Enhance Complex Walking and Reduce Fall Risk in Patients With Parkinson's Disease?
Mirelman et al.
J Gerontol A Biol Sci Med Sci 2011;66A:234-240.
ABSTRACT | FULL TEXT